



Reaching lower limits of quantification by LC-MS/MS : The quest for sensitivity

Jason Bilodeau

Young Scientists Symposium
November 17, 2015



Presentation overview

- Introduction
- LC-MS/MS Optimization
- Sample extraction
- More sensitivity
- Case studies
- Conclusion

Introduction

- What is a lower limit of quantification (LLOQ)?
 - The lowest concentration of an analyte that can be quantified with acceptable precision and accuracy.

- Some history
 - 10 years ago : In the low ng/mL range.
 - 5 years ago : In the low pg/mL range.
 - Now : In the fg/mL range.




LC-MS/MS


- Mass spectrometric (MS) detection is the gold standard for bioanalytical methods since many years
- Widely used in R&D to provide structural information
- The advantages of using LC-MS/MS :
 - This complex design isolates the primary ionic species (parent ion).
 - The MRM (multiple reaction monitoring) mode offers the possibility to fragment the parent into additional ions (daughter or product ion).
 - Increased selectivity (based on m/z ratio).
 - Different LC-MS configurations (Quadrupoles, ion traps and TOF).

LC-MS/MS (Whole detector)

- Representation of a typical MS/MS system



LC-MS/MS (MS/MS optimization)



Sciex MS/MS parameters : declustering potential (DP), entrance potential (EP), collision energy (CE) and collision cell exit potential (CXP).

LC-MS/MS (LC conditions optimization)

LC conditions

- Find LC conditions (column, MP) that give good retention time ($K' > 1$).
- Optimize peak shape.

Serial dilution

- Evaluate sensibility of analyte (LLOQ in neat solution).

More than one analyte?

Even if LC-MS/MS is a very selective method, it is recommended that all the potentially interfering co-eluting compounds are well separated to avoid problems (i.e. Ion suppression caused by phospholipids).

LC-MS/MS (MS/MS fine-tuning)

- The MS/MS fine-tuning is a long and tedious process, but it's worth it
- All the sources must be optimized
 - Two identical MS/MS (i.e. ESI) can have different parameters.
- The MS/MS and source parameters :
 - CAD gas (Q2)
 - Curtain gas pressure
 - Nebulizer gas pressure (GS1)
 - Auxiliary gas pressure (GS2)
 - TurbolonSpray or Heated Nebulizer temperature
 - Ion spray voltage (ESI) or corona needle voltage (APCI)


LC-MS/MS (System fine-tuning)

- Here are the keys for the perfect system fine-tuning :
 - Perform this step with your optimized chromatographic conditions (Analytical column, mobile phases, flow, column T(°C) etc..).
 - One parameter at the time, inject LLOQ samples changing the parameter by small increments. Use treated samples if possible.
- Example for the TurbolonSpray temperature
 - Inject a LLOQ sample at each temperature starting at 250°C with increments of 50°C.
 - Compare the signal-to-noise of each injections. The higher the better.
 - Repeat this procedure for all parameters.

LC-MS/MS (Optimization)

- Temperature optimization (250 to 600°C with 50°C increments)

Analyte



250°C


450°C

600°C

IS

Case studies (Dexamethasone in human plasma EDTA K₂)

- Sensitivity improvement
 - Old method LLOQ : 10 pg/mL
 - Improved method LLOQ : 0.5 pg/mL
 - Liquid-Liquid extraction
 - Concentration factor : 2x vs 10x



| Human Method | |
|-----------------------------|---|
| Chromatographic mode | Reverse Phase |
| Analytical Column | ACE Excel 2 C18 50 x 3.0 mm |
| Elution mode | Isocratic |
| Mobile Phase A | Methanol/Water/Ammonium formate/Formic Acid 0.1% |
| Flow Rate | 0.550 mL/min |
| Injection volume | 40 uL |
| Retention Time | 1.78 min for Dexamethasone 1.75 for Dexamethasone-d ₄ |
| Acquisition time: | 4.00 min |
| Detector: | API 5000 |
| Source: | TurboIonSpray |
| Ion Monitored: | 393→373 for Dexamethasone 397→377 for Dexamethasone-d ₄ |

Gain from extraction :
5x

Gain from chromatography :
2x

Gain from optimisation :
2x

Case studies (Dexamethasone in human plasma EDTA K₂)

LLOQ (500 fg/mL)




Figure 1. Representative Chromatogram of a Calibration Standard at 0.500 pg/mL in Human EDTA K₂ Plasma

Blank




Figure 2. Representative Chromatogram of a Blank Human EDTA K₂ Plasma



Extraction

- 3 main types of extraction
 - Protein precipitation extraction (PPE)
 - Liquid-Liquid extraction (LLE)
 - Solid-phase extraction (SPE)
- The cleaner the final extract is, the lower will be your noise
- Evaporation to dryness gives the possibility to concentrate the sample


More sensitivity

- Possibility to form adducts
 - Ammonia $[M+NH_4]^+ = m/z$ of $[M+18]^+$
 - Sodium $[M+Na]^+ = m/z$ of $[M+23]^+$
 - Potassium $[M+K]^+ = m/z$ of $[M+39]^+$
- Mass summation
 - In some cases, adding different transitions improves signal-to-noise.
- Derivatization
 - Various functional groups can be chemically added to the drug of interest.

Case studies (Mometasone furoate in human plasma EDTA K₂)

- Extraction

- Internal standard : Mometasone furoate-d₃
- Sample volume : 1000 µL
- Liquid-Liquid extraction followed by a solid-phase extraction
- Concentration factor : 10




| | Old Method | Improved Method |
|-------------------|---|---|
| Analytical Range | 2-100 pg/mL | 250-50000 fg/mL |
| Analytical Column | ACE 3 C18, 50x4.6mm, 3µm | ACE Excel 2 C18, 50 x 3.0 mm, 2 µm |
| Elution Mode | HPLC Gradient | UPLC Gradient |
| Mobile Phase A | Water/Methanol (10/90), Na Acetate 0.2M | Milli-Q type Water, Sodium Acetate 1 mM |
| Mobile Phase B | Water/Methanol (30/70), Na Acetate 0.2M | Methanol 100% |
| Flow Rate | 1 mL/min | 0.65 mL/min |
| Injection Volume | 30 µL | 40 µL |
| Retention Time | 2.64 minutes | 1.74 minutes |
| Ion Monitored | 543→ 507 amu | 543→ 507 amu |
| Ionization Mode | Positive TurbolonSpray | Positive TurbolonSpray |

Case studies (Mometasone furoate in human plasma EDTA K₂)

- Extraction

- Internal standard : Mometasone furoate-d₃
- Sample volume : 1000 µL
- Liquid-Liquid extraction followed by a solid-phase extraction
- Concentration factor : 10




| | Old Method | Improved Method |
|-------------------|---|---|
| Analytical Range | 2-100 pg/mL | 250-50000 fg/mL |
| Analytical Column | ACE 3 C18, 50x4.6mm, 3µm | ACE Excel 2 C18, 50 x 3.0 mm, 2 µm |
| Elution Mode | HPLC Gradient | UPLC Gradient |
| Mobile Phase A | Water/Methanol (10/90), Na Acetate 0.2M | Milli-Q type Water, Sodium Acetate 1 mM |
| Mobile Phase B | Water/Methanol (30/70), Na Acetate 0.2M | Methanol 100% |
| Flow Rate | 1 ml/min | 0.65 ml/min |
| Injection Volume | 30 µL | 40 µL |
| Retention Time | 2.64 minutes | 1.74 minutes |
| Ion Monitored | 543→ 507 amu | 543→ 507 amu |
| Ionization Mode | Positive TurbolonSpray | Positive TurbolonSpray |

Case studies (Mometasone furoate in human plasma EDTA K₂)

- Extraction

- Internal standard : Mometasone furoate-d₃
- Sample volume : 1000 µL
- Liquid-Liquid extraction followed by a solid-phase extraction
- Concentration factor : 10



| | Old Method | Improved Method |
|-------------------|---|---|
| Analytical Range | 2-100 pg/mL | 250-50000 fg/mL |
| Analytical Column | ACE 3 C18, 50x4.6mm, 3µm | ACE Excel 2 C18, 50 x 3.0 mm, 2 µm |
| Elution Mode | HPLC Gradient | UPLC Gradient |
| Mobile Phase A | Water/Methanol (10/90), Na Acetate 0.2M | Milli-Q type Water, Sodium Acetate 1 mM |
| Mobile Phase B | Water/Methanol (30/70), Na Acetate 0.2M | Methanol 100% |
| Flow Rate | 1 mL/min | 0.65 mL/min |
| Injection Volume | 30 µL | 40 µL |
| Retention Time | 2.64 minutes | 1.74 minutes |
| Ion Monitored | 543→ 507 amu | 543→ 507 amu |
| Ionization Mode | Positive TurbolonSpray | Positive TurbolonSpray |

Sodium Adduct

Case studies (Mometasone furoate in human plasma EDTA K₂)

Old method (2 pg/mL)

New method (0.25 pg/mL)






Figure 3. Chromatogram of the LLOQ (2 pg/mL) using the old Chromatographic Conditions

Figure 2. Chromatogram of the LLOQ (250 fg/mL) using the New UPLC Conditions


Case studies (Alendronic acid in urine)

- Case with a derivatization (diazomethane)
 - Dynamic range : 1-1000 ng/mL



Alendronic Acid
MW: 249.1 g/mol

Methylation
Diazomethane



Methylated Alendronic Acid
MW: 333.2 g/mol


Case studies (Alendronic acid in urine)

- On-cartridge derivatization
 - Internal standard : Alendronic acid-d₆
 - Solid phase extraction with Oasis WAX 60mg

LC-MS/MS Analysis


| | |
|----------------------|---|
| Chromatographic mode | Cation exchange |
| Analytical Column: | Zorbax 300 SCX, 50 x 3 mm, 5 µm |
| Elution mode: | Gradient |
| Mobile Phase A: | Milli-Q Type Water / Acetonitrile (25/75), Ammonium acetate 3 mM, Acetic Acid 0.1% (v/v) |
| Mobile Phase B: | Milli-Q Type Water / Acetonitrile (25/75), Ammonium acetate 40 mM, Acetic Acid 0.1% (v/v) |
| Flow Rate: | 1.5 mL/min for mobile phase A 2.0 mL/min for mobile phase B |
| Injection volume: | 10 µL |
| Retention Time: | 2.6 min |
| Ion Monitored: | 334.2 → 208.1 amu for Alendronic Acid 340.2 → 214.1 amu for the Internal Standard |
| Detector: | MDS Sciex API 4000 |
| Source: | TurboIonSpray, Positive mode |

Extraction






Case studies (Alendronic acid in urine)

- Advantages of the on-cartridge derivatization
 - Better methylation efficiency than off-cartridge derivatization
 - Increase of the retention time
 - Increase in sensitivity



Case studies (Mass summation)



Case studies (Mass summation)

| | Digoxin | Lacidipine | Triamcinolone acetonide |
|-----------------------|---|--|--|
| Ion monitored | [M + H] ⁺ : 781.3 → 651.3 amu [M + NH ₄] ⁺ : 798.3 → 651.3 amu | [M + H] ⁺ : 456.3 → 354.1 amu [M + NH ₄] ⁺ : 473.3 → 354.1 amu | 435.3 → 415.2 amu 435.3 → 397.2 amu |
| State file parameters | [M + H] ⁺ : DP=60; EP=10; CE=13; CXP=9; ISV= 3250 [M + NH ₄] ⁺ : DP=60; EP=5; CE=20; CXP=9; ISV=3250 | [M + H] ⁺ : DP=78; EP=10; CE=13; CXP=12; ISV= 5500 [M + NH ₄] ⁺ : DP=61; EP=10; CE=17; CXP=12; ISV=5500 | 435.3 → 415.2: DP=50; EP=10; CE=16; CXP=12 435.3 → 397.2: DP=50; EP=10; CE=21; CXP=12 |
| Source | TurbolonSpray | TurbolonSpray | Heated Nebulizer |
| Mode | Positive | Positive | Positive |
| Mass spectrometer | API 4000 | API 4000 | API 4000 |

Case studies (Mass summation)

| | Digoxin | | Lacidipine | | Triamcinolone Acetonide | |
|----------------------------------|----------------------|--|----------------------|--|-------------------------|-----------------------|
| | LLOQ: 100 pg/mL | | LLOQ: 50 pg/mL | | LLOQ: 100 pg/mL | |
| | [M + H] ⁺ | [M + H] ⁺ + [M + NH ₄] ⁺ | [M + H] ⁺ | [M + H] ⁺ + [M + NH ₄] ⁺ | 435 → 415 | 435 → 415 + 435 → 397 |
| Mean response (n=6) | 967.7 | 2106.0 | 1311.7 | 2947.3 | 1931.2 | 2652.0 |
| CV (%) | 11.43 | 6.00 | 18.19 | 8.23 | 4.08 | 5.15 |
| Mean signal to noise ratio (n=6) | 16 | 32 | 8 | 23 | 40 | 53 |



Conclusion

- LC-MS/MS is a very useful tool for bioanalytical methods
- A perfect MS/MS and source fine-tuning are required to reach the lowest LLOQs
- A cleaner extraction will help to decrease the noise
- Adducts, mass summation and derivatization are good alternatives to get more signal to noise



Acknowledgements

- InVentiv Health Clinical
- Our R&D team
 - Pierre-Yves Caron
 - Luc Bouchard
 - Nicolas Jean
 - François Samson-Thibault
 - Sylvain Lachance
 - Nadine Boudreau
- The YSS organization committee
- The audience



Questions?